Belskaya G N
Research Center of Neurology, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(10):117-122. doi: 10.17116/jnevro2021121101117.
Currently, both in Russia and in the world as a whole, the problem of acute and chronic cerebrovascular pathology does not lose its relevance, despite the organizational measures taken to prevent and treat this pathology. The search for highly effective methods of treating stroke patients continues, while preference is given to drugs with polymodal neuroprotective, neuroreparative effects. In this regard, the promising Russian drug cellex, obtained from the embryonic brain tissue of pigs, is of interest. The drug contains tissue-specific signaling proteins and polypeptides (growth factors, differentiation of nerve cells). The article presents the results of a number of experimental and clinical studies proving its primary and secondary neuroprotective effects. In multicenter Russian studies, including placebo-controlled studies, convincing data were obtained on the effectiveness and safety of the drug in the acute and recovery periods of ischemic and hemorrhagic stroke, as well as in chronic brain ischemia. Based on the analysis of the results obtained during the research, it is concluded that it is advisable to use drugs with a pleiotropic effect. The complex of measures that contribute to improving the effectiveness of rehabilitation measures both in the acute and in the recovery period of stroke, as well as in chronic cerebrovascular pathology, should include drugs that have neurotrophic and neuroprotective properties. They significantly contribute to the activation of neuroplasticity capabilities, thereby providing a powerful therapeutic effect. One of the drugs in this group is cellex, which has a decent evidence base of effectiveness and safety.
目前，在俄罗斯乃至全球范围内，急性和慢性脑血管疾病问题仍然具有现实意义，尽管已采取了预防和治疗该疾病的组织措施。对中风患者高效治疗方法的探索仍在继续，同时更倾向于使用具有多模式神经保护、神经修复作用的药物。在这方面，从猪胚胎脑组织中提取的俄罗斯有前景的药物“细胞素”（cellex）备受关注。该药物含有组织特异性信号蛋白和多肽（生长因子、神经细胞分化因子）。本文介绍了一系列实验和临床研究结果，证明了其一级和二级神经保护作用。在包括安慰剂对照研究在内的俄罗斯多中心研究中，获得了令人信服的数据，证明该药物在缺血性和出血性中风的急性期和恢复期以及慢性脑缺血中具有有效性和安全性。基于对研究期间所得结果的分析，得出使用具有多效性作用的药物是明智的结论。有助于提高中风急性期和恢复期以及慢性脑血管疾病康复措施有效性的综合措施，应包括具有神经营养和神经保护特性的药物。它们显著有助于激活神经可塑性能力，从而产生强大的治疗效果。该类药物之一就是“细胞素”，其有效性和安全性有充分的证据基础。
